Federal Court Ruling Clears Way For Wellbutrin XL Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
Judge declines to block FDA from approving generic version of GSK/Biovail’s bupropion extended-release.
You may also be interested in...
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?
As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures
Teva's Generic Wellbutrin XL For Major Depressive Disorder Launches
GSK has more than two years to market Wellbutrin XL in seasonal affective disorder before generics for that indication can launch.